The present invention relates to compound of Formula (I) ##STR00001##
containing carbon-carbon linker, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, N-oxide, S-oxide, or a carboxylic acid isostere thereof; processes for their preparation; pharmaceutical compositions comprising said compounds; and their use for the treatment of the diseases or disorders mediated by GPR120 receptor.

The present invention relates to compound of Formula (I) ##STR00001##
containing carbon-carbon linker, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, N-oxide, S-oxide, or a carboxylic acid isostere thereof; processes for their preparation; pharmaceutical compositions comprising said compounds; and their use for the treatment of the diseases or disorders mediated by GPR120 receptor.

A polymerizable liquid crystal composition capable of manufacturing an optically anisotropic film having excellent light fastness; and an optically anisotropic film, an optical film, a polarizing plate, an image display device, and an organic electroluminescent display device, each of which uses the polymerizable liquid crystal composition. The polymerizable liquid crystal composition of an embodiment of the present invention contains a polymerizable liquid crystal compound having reverse-wavelength dispersion properties and an aromatic polyether-based compound.

A polymerizable liquid crystal composition capable of manufacturing an optically anisotropic film having excellent light fastness; and an optically anisotropic film, an optical film, a polarizing plate, an image display device, and an organic electroluminescent display device, each of which uses the polymerizable liquid crystal composition. The polymerizable liquid crystal composition of an embodiment of the present invention contains a polymerizable liquid crystal compound having reverse-wavelength dispersion properties and an aromatic polyether-based compound.

The present invention relates to the discovery of compounds that can be used to treat and/or prevent heart failure in a subject. In certain embodiments, the compounds of the invention are sulfide:quinone oxidoreductase (SQOR) inhibitors. In other embodiments, the compounds of the invention increase physiological levels of H.sub.2S in the subject. In yet other embodiments, administration of the compounds of the invention treats, ameliorates, and/or prevents hypertension, and/or atherosclerosis, and/or pathological cardiac remodeling that leads to heart failure in the subject.

Provided are an ultraviolet absorbing agent represented by General Formula (1) and an application thereof. In General Formula (1), R.sup.11 represents a monovalent substituent. n is 1 or 2. W.sup.1 and W.sup.2 each independently represent a hydrogen atom, a cyano group, a carbamoyl group, a sulfamoyl group, a nitro group, an acyl group, an alkylsulfonyl group, an arylsulfonyl group, an alkylsulfinyl group, an arylsulfinyl group, an alkoxycarbonyl group, an aryloxycarbonyl group, an alkyl group, an aryl group, or a heterocyclic group, where at least one of W.sup.1 or W.sup.2 represents a substituent having a Hammett's substituent constant σp value of 0.2 or more. W.sup.1 and W.sup.2 may be bonded to each other to form a ring.

##STR00001##

Provided are an ultraviolet absorbing agent represented by General Formula (1) and an application thereof. In General Formula (1), R.sup.11 represents a monovalent substituent. n is 1 or 2. W.sup.1 and W.sup.2 each independently represent a hydrogen atom, a cyano group, a carbamoyl group, a sulfamoyl group, a nitro group, an acyl group, an alkylsulfonyl group, an arylsulfonyl group, an alkylsulfinyl group, an arylsulfinyl group, an alkoxycarbonyl group, an aryloxycarbonyl group, an alkyl group, an aryl group, or a heterocyclic group, where at least one of W.sup.1 or W.sup.2 represents a substituent having a Hammett's substituent constant σp value of 0.2 or more. W.sup.1 and W.sup.2 may be bonded to each other to form a ring.

##STR00001##

The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula (I) is administered to the patient together with one or more additional active agents.

The invention relates to new types of modulators of the cold menthol receptor TRPM8, to methods of modulating the TRPM8 receptor using these modulators; and in particular the use of the modulators for inducing a sensation of coldness; and also the articles and compositions produced using these modulators.

The invention relates to new types of modulators of the cold menthol receptor TRPM8, to methods of modulating the TRPM8 receptor using these modulators; and in particular the use of the modulators for inducing a sensation of coldness; and also the articles and compositions produced using these modulators.